BioNTech (NASDAQ:BNTX) Shares Down 2.3% – Here’s What Happened

BioNTech SE (NASDAQ:BNTX) shares traded down 2.3% during mid-day trading on Monday . The company traded as low as $116.45 and last traded at $117.63. 159,342 shares were traded during trading, a decline of 80% from the average session volume of 805,760 shares. The stock had previously closed at $120.38.

Analyst Ratings Changes

BNTX has been the topic of a number of recent research reports. TD Cowen reduced their target price on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. UBS Group raised their target price on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th. BMO Capital Markets reissued an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. Finally, Canaccord Genuity Group lifted their price objective on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a report on Wednesday, November 27th. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $140.76.

BioNTech Trading Down 4.9 %

The stock has a market cap of $26.53 billion, a P/E ratio of -53.15 and a beta of 0.22. The firm’s 50 day simple moving average is $113.66 and its two-hundred day simple moving average is $100.66. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same quarter in the prior year, the firm earned $0.73 EPS. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. As a group, equities research analysts predict that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Large investors have recently added to or reduced their stakes in the stock. Planning Capital Management Corp increased its stake in shares of BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares during the period. Blue Trust Inc. grew its holdings in BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares in the last quarter. GAMMA Investing LLC increased its position in BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after acquiring an additional 111 shares during the period. Daiwa Securities Group Inc. increased its position in BioNTech by 430.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock valued at $155,000 after acquiring an additional 1,562 shares during the period. Finally, Caprock Group LLC bought a new stake in BioNTech during the 2nd quarter valued at $206,000. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.